Speaking about the clinical utility of DNA methylation in cutaneous melanoma, some attempts have already been made in this direction: i.e., the RASSF1A promoter hypermethylation tracked in the cfDNA has been found to be a good diagnostic and prognostic biomarker [78,95]. The gene discussed is RASSF1; the disease is cutaneous melanoma.